Results 51 to 60 of about 126,887 (307)
Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors [PDF]
Journal of Immunotherapy and Precision Oncology, 2020 A major breakthrough in cancer treatment was ushered in by the development of immune checkpoint blockade therapy such as anti-CTLA4 antibody and anti-PD-1 and anti-programmed cell death-ligand 1 antibodies that are now approved for use in an increasing ...
Kathrina L. Marcelo-Lewis +2 more
doaj +1 more source
Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]
, 2016 Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios +4 more
core +3 more sources
Combination approaches with immune checkpoint blockade in cancer therapy
Frontiers in Oncology, 2016 In healthy individuals, immune checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules to evade eradication by the immune system.
Maarten Swart +2 more
doaj +1 more source
Open Biology, 2021 Radiation has been a pillar of cancer therapy for decades. The effects of radiation on the anti-tumour immune response are variable across studies and have not been explicitly defined in poorly immunogenic tumour types.
Courtney T. Stump +3 more
doaj +1 more source
CD8+ T-cell responses in vaccination: Reconsidering targets and function in the context of chronic antigen stimulation [PDF]
, 2018 Cytotoxic CD8 T cells play important roles in eliminating infected and transformed cells. Owing to their potential for therapeutic applications, significant efforts are dedicated toward developing CD8 T cell-based vaccines.
Cosma, Gabriela L., Eisenlohr, Laurence
core +2 more sources
Frontiers in Cell and Developmental Biology, 2021 Extrinsic factors such as expression of PD-L1 (programmed dealth-ligand 1) in the tumor microenvironment (TME) have been shown to correlate with responses to checkpoint blockade therapy.
Bjarne Bartlett +11 more
doaj +1 more source
Frontiers in Oncology, 2019 Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially ...
Jan-Michael Werner +14 more
doaj +1 more source
Revving up dendritic cells while braking PD-L1 to jump-start the cancer-immunity cycle motor [PDF]
, 2016 Although it is successful for some, most melanoma patients are refractory to T cell checkpoint inhibition. In this issue of Immunity, Merad and colleagues (2016) describe a dendritic-cell-based strategy to heighten the efficacy of therapeutic anti-PD-L1 ...
Coffelt, Seth B., de Visser, Karin E.
core +1 more source
The newfound relationship between extrachromosomal DNAs and excised signal circles
FEBS Letters, EarlyView.Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley +1 more source
A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm
Molecular OncologyImmune checkpoint blockade has emerged as a potent new tool in the war on cancer. However, only a subset of cancer patients benefit from this therapeutic modality, sparking a search for combination therapies to increase the fraction of responding ...
Mary C. Clark +5 more
doaj +1 more source